The deal flow by foundational CRISPR companies is providing clues into what they are prioritizing to take into the clinic.
Among the slew of programs in Cancer Moonshot, the NCI's Drug Formulary stands out for adding a new dimension to combination testing that would have been hard to come by otherwise.
EMERGING COMPANY PROFILE
Synthorx is using unnatural bases to create synthetic amino acids that can improve properties of therapeutic proteins.
TRANSLATION IN BRIEF
A new CRISPR-based method stands to revamp antibody production in hybridoma lines for faster and purer yields of mAbs.
Perthera is stepping in to act as a virtual sorting station to help physicians navigate and interpret data from the growing list of -omics labs.
NIH and HHS put up $20 million in prize money to draw all-comers to a competition to develop diagnostics for antimicrobial resistance.
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.